Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 14/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | CALML3 | P27482 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5533923 | 1.00 | MAOA (0.46) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL5526574 | 0.91 | CALML3 (0.55) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL5526570 | 0.91 | CALML3 (0.55) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL5519703 | 0.88 | MAOA (0.54) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL14436442 | 0.88 | MAOA (0.44) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL5524612 | 0.86 | MAOA (0.55) | MAOACYP3A4CYP2C9 | |
| SCHEMBL5739958 | 0.85 | MAOA (0.45) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL5521236 | 0.83 | CALML3 (0.50) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL5521247 | 0.83 | CALML3 (0.50) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL14436440 | 0.82 | MAOA (0.42) | MAOAMAOBCALML3CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185132-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo | MERCK & CO., INC. | 2007-08-09 | — | — | US | disclosed |
| EP-1654259-A1 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005005420-A1 | CYCLOPROPYL GROUP SUBSTITUTED OYAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185132-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo | IL17A, COASY, OXA1L | MAOA 2435/4885MAOB 1387/4885CALML3 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.